Ravi Jahagirdar
Suite 300, 4820 Richard Road SW
Calgary, AB T3E6L1, Canada
Calgary, AB T3E6L1, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation.
Journal: Translational neuroscience
Published: September 25, 2023
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells.
Journal: Atherosclerosis
Published: April 25, 2022
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease.
Journal: Cardiovascular therapeutics
Published: April 30, 2020
Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
Journal: American journal of respiratory and critical care medicine
Published: May 03, 2019
Apabetalone downregulates factors and pathways associated with vascular calcification.
Journal: Atherosclerosis
Published: June 29, 2018
Benefit of Apabetalone on Plasma Proteins in Renal Disease.
Journal: Kidney international reports
Published: October 18, 2017
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
Journal: Molecular pharmacology
Published: August 24, 2017
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).
Journal: Journal of cardiovascular translational research
Published: December 21, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026